Why Shares of Hibbett Sports Dropped Today

What happened

Shares of Hibbett Sports (NASDAQ:HIBB) slumped on Friday after the retailer reported lackluster first-quarter results. Hibbett missed analyst expectations across the board, with strong e-commerce sales unable to offset a decline in comparable-store sales. The stock was down about 13.8% at 11:25 a.m. EDT.

So what

Hibbett reported first-quarter revenue of $274.7 million, down 0.4% year over year and $2.65 million below the average analyst estimate. The decline was driven by a 0.3% drop in comparable-store sales and store closings. Hibbett pointed to strong growth in e-commerce sales, which now account for 7% of total sales, as one silver lining in the quarter.

Image source: Getty Images.

Earnings per share came in at $1.12, up from $0.97 in the prior-year period but $0.03 lower than analysts were expecting. A lower tax rate and share buybacks were the only reasons for the earnings growth. Gross margin slumped by 0.4 percentage points year over year, while store operating, selling, and administrative costs as a percentage of revenue jumped by 1.3 percentage points. Operating income tumbled 16.2%.

Hibbett CEO Jeff Rosenthal sounded optimistic about the second quarter: "As we start the second quarter, we believe we are well positioned with fresh assortments and easier comparisons as we prepare for the back-to-school season."

Now what

Hibbett maintained its full-year earnings guidance, which calls for earnings per share between $1.65 and $1.95. Despite the decline in margins during the first quarter, the numbers were still solid overall. Gross margin was 35.2%, while operating margin was 10.4%.

Hibbett has $115.8 million of cash and no debt on its balance sheet, putting it in a strong financial position. While investors didn't like the company's results, Hibbett has plenty of time to turn things around.

Universal Stainless & Alloy Products (USAP) Trading Down 0%

Shares of Universal Stainless & Alloy Products, Inc. (NASDAQ:USAP) traded down 0% on Friday . The company traded as low as $24.22 and last traded at $24.53. 505,097 shares were traded during trading, an increase of 1,278% from the average session volume of 36,661 shares. The stock had previously closed at $24.53.

A number of analysts have weighed in on the company. ValuEngine raised Universal Stainless & Alloy Products from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research raised Universal Stainless & Alloy Products from a “sell” rating to a “strong-buy” rating and set a $26.00 price objective for the company in a research report on Thursday, January 25th.

Get Universal Stainless & Alloy Products alerts:

The company has a quick ratio of 0.95, a current ratio of 3.97 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $199.00 million, a price-to-earnings ratio of 58.28 and a beta of 0.99.

Universal Stainless & Alloy Products (NASDAQ:USAP) last posted its quarterly earnings data on Wednesday, April 25th. The basic materials company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.09. Universal Stainless & Alloy Products had a return on equity of 1.88% and a net margin of 5.46%. The company had revenue of $63.74 million during the quarter. research analysts predict that Universal Stainless & Alloy Products, Inc. will post 1.28 EPS for the current year.

In related news, Chairman Dennis M. Oates acquired 1,059 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was bought at an average cost of $23.61 per share, with a total value of $25,002.99. Following the transaction, the chairman now owns 95,369 shares of the company’s stock, valued at $2,251,662.09. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.60% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. O Shaughnessy Asset Management LLC purchased a new position in shares of Universal Stainless & Alloy Products during the 1st quarter worth approximately $150,000. Wells Fargo & Company MN raised its stake in shares of Universal Stainless & Alloy Products by 195.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,666 shares of the basic materials company’s stock worth $143,000 after buying an additional 4,406 shares in the last quarter. Element Capital Management LLC purchased a new position in shares of Universal Stainless & Alloy Products during the 1st quarter worth approximately $213,000. Tibra Equities Europe Ltd purchased a new position in shares of Universal Stainless & Alloy Products during the 1st quarter worth approximately $421,000. Finally, Wedge Capital Management L L P NC purchased a new position in shares of Universal Stainless & Alloy Products during the 4th quarter worth approximately $364,000. 87.13% of the stock is owned by institutional investors and hedge funds.

About Universal Stainless & Alloy Products

Universal Stainless & Alloy Products, Inc, together with its subsidiaries, manufactures and markets semi-finished and finished specialty steel products in the United States and internationally. The company's products include stainless steel, nickel alloys, tool steel, and various other alloyed steels.

Top 5 Medical Stocks To Own Right Now

tags:SAGE,CYS,STOR,HPP,AGNC,

Daiwa Securities Group Inc. reduced its position in shares of Teleflex (NYSE:TFX) by 32.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,617 shares of the medical technology company’s stock after selling 8,572 shares during the period. Daiwa Securities Group Inc.’s holdings in Teleflex were worth $4,492,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Comerica Bank lifted its position in shares of Teleflex by 0.6% during the fourth quarter. Comerica Bank now owns 35,546 shares of the medical technology company’s stock worth $9,778,000 after purchasing an additional 198 shares in the last quarter. Creative Planning lifted its position in shares of Teleflex by 6.0% during the fourth quarter. Creative Planning now owns 4,119 shares of the medical technology company’s stock worth $1,025,000 after purchasing an additional 234 shares in the last quarter. Osterweis Capital Management Inc. lifted its position in shares of Teleflex by 0.3% during the fourth quarter. Osterweis Capital Management Inc. now owns 90,707 shares of the medical technology company’s stock worth $22,570,000 after purchasing an additional 242 shares in the last quarter. Barometer Capital Management Inc. lifted its position in shares of Teleflex by 3.2% during the fourth quarter. Barometer Capital Management Inc. now owns 8,075 shares of the medical technology company’s stock worth $2,009,000 after purchasing an additional 250 shares in the last quarter. Finally, Ranger Investment Management L.P. lifted its position in shares of Teleflex by 28.2% during the fourth quarter. Ranger Investment Management L.P. now owns 1,217 shares of the medical technology company’s stock worth $303,000 after purchasing an additional 268 shares in the last quarter. 90.47% of the stock is currently owned by institutional investors and hedge funds.

Top 5 Medical Stocks To Own Right Now: Sage Therapeutics, Inc.(SAGE)

Advisors' Opinion:

• [By ]

  Sage Therapeutics (SAGE) : "Let's wait and see. I can't bless it until I see more from them."

  AbbVie (ABBV) : "I want to stay away from controversy. I like Eli Lilly (LLY) ."

• [By Dan Caplinger]

  Friday was a poor day on Wall Street, as the Dow Jones Industrials fell 200 points and other major benchmarks lost about 1%. Rising bond yields were a major source of consternation among those following the financial markets, with the 10-year Treasury hitting 2.95% and helping to send mortgage rates sharply higher. Even though earnings season has gone fairly well for many companies, some investors are also starting to realize that political issues are likely to cloud the outlook for the U.S. economy in the coming months, creating more uncertainty that could stymie further market gains. Some bad news affecting individual companies also added to the negative mood. Stanley Black & Decker (NYSE:SWK), ManpowerGroup (NYSE:MAN), and Sage Therapeutics (NASDAQ:SAGE) were among the worst performers on the day. Here's why they did so poorly.

• [By Max Byerly]

  Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Chris Lange]

  Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

Top 5 Medical Stocks To Own Right Now: CYS Investments, Inc.(CYS)

Advisors' Opinion:

• [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday. Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21. MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook. Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06. Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results. Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit. BioTelemetry,
• [By Lisa Levin] Gainers Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook. Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results. O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit. Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70. Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results. BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter. SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW. Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results. CYS Investments, Inc. (NYSE: CYS)
• [By Paul Ausick]

  CYS Investments Inc. (NYSE: CYS) traded down 5.6% Thursday and posted a new 52-week low of $6.25 after closing Wednesday at $6.62. The stock’s 52-week high is $8.98. Volume was around 4.6 million, about three �times the daily average. The reported earnings last night. The shares have reversed their drop and are on track to close flat for the day or maybe even up a little.

• [By Lisa Levin] Gainers Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 22.6 percent to $3.25 in pre-market trading after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. Mattersight Corporation (NASDAQ: MATR) shares rose 23.2 percent to $2.65 in pre-market trading after the company agreed to be purchased by NICE Ltd. Comstock Resources, Inc. (NYSE: CRK) rose 21.2 percent to $5.77 in pre-market trading after the company disclosed a deal to buy oil & gas properties in North Dakota from Arkoma, Williston Drilling for about $620 million. The company also announced withdrawal of tender offers for outstanding secured notes. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 13.7 percent to $386.00 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Wednesday. Quantenna Communications, Inc. (NASDAQ: QTNA) shares rose 12.6 percent to $14.70 in pre-market trading. Quantenna is expected to release Q1 results on April 30.. BioTelemetry, Inc. (NASDAQ: BEAT) rose 11.1 percent to $37.50 in pre-market trading as the company reported stronger-than-expected earnings for its first quarter. Penn National Gaming, Inc. (NASDAQ: PENN) rose 10.4 percent to $29.00 in pre-market trading after reporting strong Q1 results. O'Reilly Automotive, Inc. (NASDAQ: ORLY) rose 9.8 percent to $250.00 in pre-market trading following upbeat Q1 profit. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 9.4 percent to $10.62 in pre-market trading as the company reported upbeat results for its first quarter. CYS Investments, Inc. (NYSE: CYS) rose 9.1 percent to $7.22 in pre-market trading after the company agreed to be acquired by Two Harbors Investment Corp (NYSE: TWO). GNC Holdings, Inc. (NYSE: GNC) rose 8.3 percent to $4.18 in pre-market trading after reporting Q1 results. Domino's Pizza, Inc. (NYSE: DPZ) shares rose 7.6 percent to $251.2
• [By Matthew Frankel]

  Mortgage real estate investment trust CYS Investments (NYSE:CYS) announced today that it had agreed to be acquired by fellow mortgage REIT Two Harbors Investment (NYSE:TWO).

Top 5 Medical Stocks To Own Right Now: STORE Capital Corporation(STOR)

Advisors' Opinion:

• [By Brian Feroldi, Leo Sun, and Demitrios Kalogeropoulos]

  Want proof? We asked these Motley Fool investors to highlight a dividend stock that pays a higher yield than Verizon. Here's why they picked�Tanger Factory Outlets (NYSE:SKT), Cedar Fair (NYSE:FUN), and�STORE Capital (NYSE:STOR).�

• [By Shane Hupp]

  Stevens Capital Management LP bought a new position in shares of STORE Capital (NYSE:STOR) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 24,795 shares of the real estate investment trust’s stock, valued at approximately $615,000.

• [By Lee Jackson]

  STORE Capital Corp. Inc. (NYSE: STOR) is the leader in the acquisition, investment and management of Single Tenant Operational Real Estate, which is its target market. Investors receive a 4.94% yield, and shares traded recently at $24.85. The 52-week range is $19.65 to $26.58. The consensus price target is $27.08.

• [By Keith Speights]

  Verizon Communications (NYSE:VZ), Store Capital Corporation (NYSE:STOR), and Sanofi (NYSE:SNY) are three Warren Buffett stocks that have especially high dividend yields of more than 4%. What does the Oracle of Omaha like about these stocks -- and are they smart picks for other investors right now?

Top 5 Medical Stocks To Own Right Now: Hudson Pacific Properties, Inc.(HPP)

Advisors' Opinion:

• [By Chris Lange]

  Hudson Pacific Properties Inc. (NYSE: HPP) was started as a Buy at Merrill Lynch.

  L Brands Inc. (NYSE: LB) was maintained as Overweight at Morgan Stanley and assigned a price target of $56 (versus a $35.22 close).

Top 5 Medical Stocks To Own Right Now: American Capital Agency Corp.(AGNC)

Advisors' Opinion:

• [By Sean Williams]

  In particular, agency-only mortgage REITs tend to be a considerably safer bet during a rising interest rate environment. This would include Annaly Capital Management, which had $90.6 billion of its $101.8 billion in total assets invested in agency mortgage-backed securities (MBS) as of Dec. 31, 2017, as well as AGNC Investment Corp. (NASDAQ:AGNC), which had $54.8 billion of its $69.3 billion investment portfolio tied up in agency MBSs. Though agency MBSs pay less given that they're protected from default, it allows Annaly Capital Management and AGNC Investment Corp. to lean on leverage to generate income. As of their most recent quarters, Annaly and AGNC sported respective leverage of 6.6-to-1 and 8.2-to-1.�

Fortinet Inc (FTNT) CEO Ken Xie Sells 50,000 Shares

Fortinet Inc (NASDAQ:FTNT) CEO Ken Xie sold 50,000 shares of the company’s stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the sale, the chief executive officer now owns 12,562,906 shares of the company’s stock, valued at $760,181,442.06. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Fortinet traded up $1.47, reaching $60.64, during mid-day trading on Thursday, Marketbeat Ratings reports. The stock had a trading volume of 2,527,800 shares, compared to its average volume of 1,659,185. The firm has a market capitalization of $9.88 billion, a PE ratio of 116.62, a P/E/G ratio of 4.12 and a beta of 0.75. Fortinet Inc has a 1-year low of $35.44 and a 1-year high of $60.82.

Get Fortinet alerts:

Fortinet (NASDAQ:FTNT) last announced its quarterly earnings data on Thursday, May 3rd. The software maker reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.09. The business had revenue of $399.00 million for the quarter, compared to analyst estimates of $390.60 million. Fortinet had a return on equity of 14.64% and a net margin of 4.01%. The company’s revenue was up 17.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 earnings per share. equities analysts expect that Fortinet Inc will post 0.85 earnings per share for the current year.

A number of equities research analysts recently weighed in on the company. UBS upped their price objective on Fortinet from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday. Barclays upped their price objective on Fortinet from $48.00 to $50.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 6th. Zacks Investment Research upgraded Fortinet from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research note on Wednesday, May 2nd. Monness Crespi & Hardt restated a “buy” rating and set a $56.00 price objective (up from $50.00) on shares of Fortinet in a research note on Wednesday, February 28th. Finally, Citigroup upped their price objective on Fortinet from $45.00 to $56.00 and gave the stock a “neutral” rating in a research note on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $54.83.

Hedge funds have recently made changes to their positions in the company. Guggenheim Capital LLC increased its holdings in shares of Fortinet by 147.4% in the fourth quarter. Guggenheim Capital LLC now owns 432,467 shares of the software maker’s stock valued at $18,895,000 after purchasing an additional 257,687 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Fortinet by 6.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 486,700 shares of the software maker’s stock valued at $21,264,000 after purchasing an additional 29,024 shares during the period. Toronto Dominion Bank increased its holdings in shares of Fortinet by 39.6% in the fourth quarter. Toronto Dominion Bank now owns 8,809 shares of the software maker’s stock valued at $385,000 after purchasing an additional 2,499 shares during the period. Thrivent Financial For Lutherans increased its holdings in shares of Fortinet by 4.9% in the fourth quarter. Thrivent Financial For Lutherans now owns 434,802 shares of the software maker’s stock valued at $18,996,000 after purchasing an additional 20,275 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Fortinet by 6.6% in the fourth quarter. UBS Asset Management Americas Inc. now owns 457,249 shares of the software maker’s stock valued at $19,977,000 after purchasing an additional 28,247 shares during the period. 69.38% of the stock is currently owned by institutional investors and hedge funds.

Fortinet Company Profile

Fortinet, Inc provides broad, automated, and integrated cybersecurity solutions worldwide. It offers FortiGate hardware and software licenses that provide various security and networking functions, including firewall, intrusion prevention, anti-malware, virtual private network, application control, Web filtering, anti-spam, and WAN acceleration; and FortiSandbox technology that delivers proactive detection and mitigation services; and FortiSIEM family of products, which offers a cloud-ready security information and event management solution for enterprises and service providers.

Insider Buying: Rosehill Resources (ROSE) Director Buys 6,700 Shares of Stock

Rosehill Resources (NASDAQ:ROSE) Director Harry Quarls acquired 6,700 shares of Rosehill Resources stock in a transaction dated Thursday, May 17th. The shares were bought at an average cost of $8.15 per share, with a total value of $54,605.00. Following the transaction, the director now owns 53,189 shares in the company, valued at $433,490.35. The purchase was disclosed in a filing with the SEC, which is available through this link.

Harry Quarls also recently made the following trade(s):

Get Rosehill Resources alerts: On Monday, May 21st, Harry Quarls acquired 10,000 shares of Rosehill Resources stock. The shares were bought at an average cost of $8.11 per share, with a total value of $81,100.00.

Shares of Rosehill Resources traded up $0.06, reaching $8.05, during trading hours on Monday, according to Marketbeat.com. The stock had a trading volume of 43,600 shares, compared to its average volume of 29,936. Rosehill Resources has a 12 month low of $5.52 and a 12 month high of $10.84. The company has a quick ratio of 0.40, a current ratio of 0.40 and a debt-to-equity ratio of 6.17. The stock has a market cap of $287.87 million, a P/E ratio of -50.31 and a beta of 1.36.

Rosehill Resources (NASDAQ:ROSE) last issued its earnings results on Monday, May 14th. The company reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $2.06. Rosehill Resources had a return on equity of 69.29% and a net margin of 5.62%. The company had revenue of $55.79 million for the quarter, compared to analysts’ expectations of $49.80 million. analysts expect that Rosehill Resources will post 1.13 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC lifted its holdings in shares of Rosehill Resources by 61.4% in the 1st quarter. Millennium Management LLC now owns 18,600 shares of the company’s stock worth $109,000 after purchasing an additional 7,075 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Rosehill Resources by 5.2% in the 1st quarter. Wells Fargo & Company MN now owns 155,546 shares of the company’s stock worth $913,000 after purchasing an additional 7,738 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Rosehill Resources by 12.6% in the 4th quarter. BlackRock Inc. now owns 131,055 shares of the company’s stock worth $1,031,000 after purchasing an additional 14,619 shares in the last quarter. Geode Capital Management LLC bought a new position in shares of Rosehill Resources in the 4th quarter worth $406,000. Finally, Quantum Capital Management lifted its holdings in shares of Rosehill Resources by 130.1% in the 1st quarter. Quantum Capital Management now owns 214,442 shares of the company’s stock worth $1,259,000 after purchasing an additional 121,233 shares in the last quarter. Institutional investors own 5.42% of the company’s stock.

Several analysts have recently commented on ROSE shares. ValuEngine raised shares of Rosehill Resources from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 18th. Eurobank EFG started coverage on shares of Rosehill Resources in a research report on Tuesday, March 6th. They set a “buy” rating and a $12.00 price objective for the company. B. Riley started coverage on shares of Rosehill Resources in a research report on Monday, February 5th. They set a “buy” rating and a $9.50 price objective for the company. Finally, Zacks Investment Research downgraded shares of Rosehill Resources from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $11.13.

About Rosehill Resources

Rosehill Resources Inc, an independent oil and natural gas company, focuses on the acquisition, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin. As of December 31, 2016, it operated 20 horizontal and 1 vertical wells in the Permian Basin; and 18 vertical and 21 horizontal wells in the Barnett Shale in the Fort Worth Basin.

Top 10 Bank Stocks To Buy For 2018

tags:MRTN,RARE,NEM,MGIC,FNSR,NYRT,DCT,URBN,TIF,PCMI,

After many years of growing profits through cost cutting, American corporations are finally embracing organic growth with capital expenditures.

In aggregate that��s good news for the market, but there will be winners and losers, according to analysts at Bank of America Merrill Lynch.

Thanks to a corporate tax windfall there��s been a surge in capex spending by large corporations during the first quarter of this year. It��s likely to persist for some time, say analysts.

Top 10 Bank Stocks To Buy For 2018: Marten Transport, Ltd.(MRTN)

Advisors' Opinion:

• [By Stephan Byrd]

  Marten Transport (NASDAQ: MRTN) and YRC Worldwide (NASDAQ:YRCW) are both small-cap transportation companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Top 10 Bank Stocks To Buy For 2018: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors' Opinion:

• [By Todd Campbell]

  A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that's successfully developed drugs for rare diseases.

• [By Chris Lange]

  Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

• [By Joseph Griffin]

  BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

  A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

Top 10 Bank Stocks To Buy For 2018: Newmont Mining Corporation(NEM)

Advisors' Opinion:

• [By Joseph Griffin]

  Boston Partners boosted its holdings in shares of Newmont Mining Co. (NYSE:NEM) by 4.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,976 shares of the basic materials company’s stock after buying an additional 2,033 shares during the quarter. Boston Partners’ holdings in Newmont Mining were worth $1,992,000 at the end of the most recent quarter.

• [By Todd Campbell]

  If these reasons have you interested in adding gold mining stocks to your portfolio, a few top companies to consider are Barrick Gold (NYSE:ABX), Randgold Resources (NASDAQ:GOLD), Newmont Mining (NYSE:NEM), Freeport McMoran (NYSE:FCX) and Goldcorp (NYSE:GG). All five could benefit if gold prices rally, so let's learn more about them.

• [By ]

  Gold miners have fought for their survival over the last several years, cutting new investments in production and trimming costs. Data from Bloomberg shows the average extraction costs at the largest miners has fallen 27% over the last five years. Tom Brady, Chief Economist at Newmont Mining (NYSE: NEM) estimates global gold production will slip by 1% annually over the next several years due to decreased capital spending by miners.

Top 10 Bank Stocks To Buy For 2018: Magic Software Enterprises Ltd.(MGIC)

Advisors' Opinion:

• [By Lisa Levin]

  Magic Software Enterprises Ltd. (NASDAQ: MGIC) is estimated to report quarterly earnings at $0.14 per share on revenue of $67.07 million.

  Canadian Solar Inc. (NASDAQ: CSIQ) is projected to report quarterly earnings at $0.47 per share on revenue of $1.34 billion.

• [By Logan Wallace]

  HC Wainwright set a $10.00 target price on Magic Software Enterprises (NASDAQ:MGIC) in a research note released on Thursday morning. The firm currently has a buy rating on the software maker’s stock.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Magic Software Enterprises (MGIC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Bank Stocks To Buy For 2018: Finisar Corporation(FNSR)

Advisors' Opinion:

• [By Peter Graham]

  Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is the�most�shorted stock on the�NASDAQ with short interest of 62.65% according to Highshortnterest.com.

• [By Paul Ausick]

  Finisar Corp. (NASDAQ: FNSR) traded down about 3.2% Tuesday and posted a new 52-week low of $15.66 after closing Monday at $16.17. The stock’s 52-week high is $29.07. Volume was less than 10% below the daily average of around 4.4 million shares. The company had no specific news.

• [By Harsh Chauhan]

  Apple is the more immediate catalyst for Lumentum as it is currently the biggest buyer of VCSEL arrays on the market. It is estimated that Apple now supplies�40% of the chipmaker's top line as compared to none at the beginning of 2017. This is because Lumentum became Apple's sole supplier thanks to a reported inability of rival Finisar (NASDAQ:FNSR) to meet�Cupertino's specifications last year. But the iPhone maker didn't want to put all its eggs in one basket.

• [By ]

  Activist investor Glenn Welling of Engaged Capital LLC, the insurgent investor agitating for changes at TiVo, Rent-a-Center, on Tuesday, May 15, revealed new positions in Aratana Therapeutics Inc. (PETX) , Cross Country Healthcare Inc. (CCRN)  and Finisar Corp. (FNSR)

• [By Leo Sun]

  That buyout was considered a major blow to Finisar (NASDAQ:FNSR), which was�also reportedly mulling a bid for Oclaro. I'm not saying Finisar will buy Acacia, but the latter's enterprise value of $740 million makes it a feasible takeover target for bigger fiber players.

Top 10 Bank Stocks To Buy For 2018: New York REIT, Inc.(NYRT)

Advisors' Opinion:

• [By Max Byerly]

  New York REIT (NYSE:NYRT) reached a new 52-week high and low on Monday . The stock traded as low as $17.51 and last traded at $17.60, with a volume of 7341 shares traded. The stock had previously closed at $17.85.

Top 10 Bank Stocks To Buy For 2018: DCT Industrial Trust Inc(DCT)

Advisors' Opinion:

• [By Stephan Byrd]

  Daiwa Securities Group Inc. lifted its holdings in DCT Industrial Trust Inc (NYSE:DCT) by 25.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 19,700 shares of the real estate investment trust’s stock after purchasing an additional 4,000 shares during the period. Daiwa Securities Group Inc.’s holdings in DCT Industrial Trust were worth $1,110,000 at the end of the most recent quarter.

• [By ]

  For an "Executive Decision" segment, Cramer spoke with Hamid Moghadam, chairman and CEO of the logistics REIT, Prologis Inc.  (PLD) , which recently announced the acquisition of DCT Industrial Trust (DCT) .

• [By Joseph Griffin]

  Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of DCT Industrial Trust Inc (NYSE:DCT) by 7.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,570 shares of the real estate investment trust’s stock after acquiring an additional 1,044 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in DCT Industrial Trust were worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

Top 10 Bank Stocks To Buy For 2018: Urban Outfitters Inc.(URBN)

Advisors' Opinion:

• [By Chris Lange]

  Urban Outfitters Inc. (NASDAQ: URBN) is scheduled to release its most recent quarterly results after the markets close on Tuesday. The consensus estimates from Thomson Reuters call for $0.63 in earnings per share (EPS) on $1.08 billion in revenue. In the fourth quarter of last year, the retailer said it had EPS of $0.55 and $1.03 billion in revenue.

• [By Logan Wallace]

  Investors sold shares of Urban Outfitters (NASDAQ:URBN) on strength during trading on Thursday. $17.36 million flowed into the stock on the tick-up and $38.83 million flowed out of the stock on the tick-down, for a money net flow of $21.47 million out of the stock. Of all equities tracked, Urban Outfitters had the 26th highest net out-flow for the day. Urban Outfitters traded up $0.44 for the day and closed at $42.76

• [By ]

  In the mid-level, Boss said that Urban Outfitters (URBN) is recovering, along with Kohl's Stores (KSS) . He also liked PVH (PVH) and Lululemon Athletica (LULU) .

• [By Chris Lange]

  Urban Outfitters Inc. (NASDAQ: URBN) also will report its most recent quarterly results on Tuesday. The consensus estimates call for $0.63 in EPS and $1.08 billion in revenue. Shares were last seen trading at $36.48, in a 52-week range of $16.19 to $38.06. The consensus price target is $34.62.

Top 10 Bank Stocks To Buy For 2018: Tiffany & Co.(TIF)

Advisors' Opinion:

• [By ]

  HSBC's top stocks list is mostly dominated by large-cap plays that happen to pay attractive dividend yields. More importantly, the stocks already have a decent amount of momentum behind them: the average one-month performance is +5.5%. 

  Baker Hughes (BHGE) Tiffany & Co. (TIF) The Mosaic Company (MOS) Deutsche Telekom Schneider Electric Adidas (ADDYY) Unicredit  CRH (CRH) Luftansa  GlaxosmithKline (GSK) Associated British Foods   Fresnillo China Construction Bank China Overseas Land & Inv. Geely Automobile Holdings CRCC China Resources Beer Samsung Electronic Sasol Adani Ports and SEZ

• [By Chris Lange]

  The S&P 500 stock posting the largest daily percentage loss ahead of the close Friday was Tiffany & Co. (NYSE: TIF) which traded down 5% at $97.51. The stock��s 52-week range is $84.15 to $111.44. Volume was 7.8 million compared to the daily average volume of 1.3 million.

• [By Shane Hupp]

  First Eagle Investment Management LLC trimmed its holdings in shares of Tiffany & Co. (NYSE:TIF) by 0.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,798,751 shares of the specialty retailer’s stock after selling 29,056 shares during the period. First Eagle Investment Management LLC owned 3.06% of Tiffany & Co. worth $370,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• [By Taylor Cox]

  Notable Earnings

  Tiffany & Co. (NYSE: TIF) Q1 premarket Ralph Lauren Corporation (NYSE: RL) Q4 premarket Target Corporation (NYSE: TGT) Q1 premarket Lowe’s Companies, Inc (NYSE: LOW) Q1 premarket L Brands, Inc (NYSE: LB) Q1 after hours NetApp, Inc (NASDAQ: NTAP) Q4 after hours

  IPOs

• [By Chris Lange]

  Look for Tiffany & Co.’s (NYSE: TIF) fiscal fourth-quarter report on Friday. The consensus forecast is $1.64 in EPS on $1.31 billion in revenue. Shares last traded at $101.76. The consensus price target is $111.88, and shares have traded between $84.15 and $111.44 in the past 52 weeks.

• [By JJ Kinahan]

  It’s all retail all the time this week, with Kohl’s Corporation (NYSE: KSS), Target Corporation (NYSE: TGT), Lowe’s Companies, Inc. (NYSE: LOW), Gap Inc. (NYSE: GPS), Foot Locker, Inc. (NYSE: FL), and Tiffany & Co (NYSE: TIF) among the big names scheduled to report. Last week saw mixed signals from retailers, with Macy’s Inc. (NYSE: M) and Walmart Inc. (NYSE: WMT) both delivering impressive results while J.C. Penney Company Inc. (NYSE: JCP) and Nordstrom, Inc. (NYSE: JWN) received poor reviews from the Street. TGT is arguably the biggest one to watch in the days ahead (see more detail below).

Top 10 Bank Stocks To Buy For 2018: PCM, Inc.(PCMI)

Advisors' Opinion:

• [By Lisa Levin]

  Thursday afternoon, the information technology shares gained 2.42 percent. Meanwhile, top gainers in the sector included PCM, Inc. (NASDAQ: PCMI), up 17 percent, and Advanced Micro Devices, Inc. (NASDAQ: AMD), up 13 percent.

• [By Shane Hupp]

  PCM (NASDAQ: PCMI) is one of 20 publicly-traded companies in the “Catalog & mail-order houses” industry, but how does it compare to its competitors? We will compare PCM to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

• [By Lisa Levin]

  On Thursday, the information technology shares gained 2.23 percent. Meanwhile, top gainers in the sector included PCM, Inc. (NASDAQ: PCMI), up 17 percent, and Advanced Micro Devices, Inc. (NASDAQ: AMD), up 14 percent.

• [By Lisa Levin]

  Thursday morning, the information technology shares gained 1.72 percent. Meanwhile, top gainers in the sector included PCM, Inc. (NASDAQ: PCMI), up 17 percent, and Advanced Micro Devices, Inc. (NASDAQ: AMD), up 13 percent.

Synovus Financial Corp Reduces Holdings in AstraZeneca (AZN)

Synovus Financial Corp cut its holdings in AstraZeneca (NYSE:AZN) by 43.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,319 shares of the company’s stock after selling 4,098 shares during the quarter. Synovus Financial Corp’s holdings in AstraZeneca were worth $186,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of AZN. Atria Investments LLC raised its position in AstraZeneca by 26.3% in the fourth quarter. Atria Investments LLC now owns 33,495 shares of the company’s stock worth $1,162,000 after acquiring an additional 6,979 shares in the last quarter. Bank of Montreal Can raised its position in AstraZeneca by 243.4% in the fourth quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after acquiring an additional 294,246 shares in the last quarter. Naples Global Advisors LLC raised its position in AstraZeneca by 6.2% in the fourth quarter. Naples Global Advisors LLC now owns 30,133 shares of the company’s stock worth $1,046,000 after acquiring an additional 1,752 shares in the last quarter. Ingalls & Snyder LLC bought a new stake in AstraZeneca in the fourth quarter worth about $865,000. Finally, Fisher Asset Management LLC raised its position in AstraZeneca by 2.7% in the fourth quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after acquiring an additional 315,759 shares in the last quarter. Hedge funds and other institutional investors own 15.18% of the company’s stock.

Get AstraZeneca alerts:

AstraZeneca opened at $36.33 on Friday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. The stock has a market cap of $92.30 billion, a price-to-earnings ratio of 8.51, a P/E/G ratio of 1.94 and a beta of 0.61. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $36.75.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, May 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.20. The firm had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $5.24 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The business’s revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS. sell-side analysts expect that AstraZeneca will post 1.7 earnings per share for the current year.

Several equities research analysts have commented on AZN shares. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets set a $40.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, March 22nd. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Monday, March 19th. Sanford C. Bernstein boosted their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Jefferies Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and boosted their price target for the stock from $28.43 to $36.70 in a research report on Monday, March 19th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.12.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca (NYSE:AZN).